Clinical trial CANFOUR
An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Cantargia AB |
| EudraCT Identifier | 2017-001111-36 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03267316 |
| Inclusion criteria | Metastatic |
| Last update |